Glofitamab in R/R DLBCL: updated safety and efficacy data

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Relapsed and Refractory Diffuse Large B-Cell LymphomaПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumabПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

Updated efficacy data on glofitamab step-up dosing in NHLПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Efficacy and safety of glofitamab for patients with Richter’s transformationПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell LymphomaПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее